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Abstract
Cardiovascular disease (CVD) is common in patients with diabetes mellitus (DM)
and related clinical outcomes are worse compared with non-diabetics. The opti-
mal treatment in diabetic patients with coronary heart disease (CHD) is cur-
rently not established. We searched MEDLINE (1975-2010) using the key terms
diabetes mellitus, coronary heart disease, revascularization, coronary artery
bypass, angioplasty, coronary intervention and medical treatment. Most stud-
ies comparing different revascularization procedures in patients with CHD
favoured coronary artery bypass graft (CABG) surgery in patients with DM. How-
ever, most of this evidence comes from subgroup analyses. Recent evidence
suggests that advanced percutaneous coronary intervention (PCI) techniques
along with best medical treatment may be non-inferior and more cost-effective
compared with CABG. Treatment of vascular risk factors is a key option in terms
of improving CVD outcomes in diabetic patients with CHD. The choice between
medical therapy and revascularization warrants further assessment.
K Ke ey y   w wo or rd ds s: :   diabetes, coronary heart disease, acute coronary syndrome, coronary
artery bypass graft, percutaneous coronary intervention, statin.
Introduction
Approximately 30% of patients with coronary heart disease (CHD) have
type 2 diabetes mellitus (T2DM) and the prevalence of impaired glucose
metabolism in this population is even higher [1-3]. Despite the consider-
able improvement in the management of cardiovascular disease (CVD),
patients with T2DM have not benefited to the same extent as those with-
out T2DM [4]. Possible explanations are that T2DM patients are under-
treated with evidence-based medications or revascularization and/or that
these treatments are less effective in T2DM [5-10].
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Despite  the  fact  that  patients  with  T2DM
account for approximately 25% of the nearly 1.5 mil-
lion coronary revascularization procedures per-
formed each year in the US, there is a relative lack
of consistent data from randomized controlled tri-
als (RCTs) comparing coronary artery bypass graft
(CABG) surgery or percutaneous coronary inter-
vention (PCI) with medical treatment alone in dia-
betic patients with either stable CHD or acute coro-
nary syndromes (ACS) [11]. Therefore, the question
remains  whether  one  of  the  revascularization
options is superior to the other in patients with
T2DM. Furthermore, does revascularization provide
additional benefit in diabetic patients who are on
optimal medical treatment? This review considers
these issues.
Search study
We searched MEDLINE (1975-2010) using the key
terms diabetes mellitus, coronary heart disease,
revascularization, coronary artery bypass, angio-
plasty, coronary intervention and medical treatment.
Reference lists of the identified trials, review arti-
cles and guidelines from official societies (includ-
ing those of the American College of Cardiology
(ACC), American Heart Association (AHA), and 
Transcatheter Cardiovascular Therapeutics) were
reviewed. To compare CABG surgery with PCI we
identified all randomized and controlled studies
which recruited patients with DM with an indica-
tion for coronary revascularization. A similar search
was performed to identify all RCTs comparing the
use of statins in patients with DM undergoing
revascularization procedures. MEDLINE searches
were also performed to identify studies, meta-analy-
ses and review articles that addressed outcomes in
patients with DM undergoing revascularization in
specific situations, for example ACS or stable CHD. 
Studies assessing revascularization in diabetes
(Table I)
A very recent analysis of a registry from Poland
reported data from 7,193 patients with ACS; 877
(12.2%) had DM on admission [10]. Diabetic patients
were older and had a higher prevalence of hyper-
lipidaemia and previous myocardial infarction (MI)
compared with non-diabetic patients (p < 0.0001
for all) [10]. Patients with DM were also more like-
ly to be women, have more extensive CHD, renal
failure, shock at presentation and to be admitted
late (p < 0.0001 for all) [10]. Despite their adverse
risk profile, diabetic patients were less frequently
treated with primary PCI with stenting (p < 0.0001)
[10]. Moreover, DM was independently associated
with impaired epicardial reperfusion (odds ratio (OR)
=  1.33;  95%  confidence  interval  (CI)  1.07-1.64, 
p = 0.009) [10]. At mean follow-up of 524 ±194 days,
patients with DM had a higher mortality rate com-
pared with non-diabetic patients (adjusted cumu-
lative mortality: 13.3% vs. 10.7%, adjusted hazard
ratio (HR) = 1.23; 95% CI 1.04-1.46, p = 0.013) [10].
Regarding the optimal revascularization strate-
gy in patients with T2DM, the Bypass Angioplasty
Revascularization Investigation (BARI) trial com-
pared  CABG  with  percutaneous  transluminal 
coronary angioplasty (PTCA) in 1,829 patients with
multivessel CHD (64% had ACS) [12]. In a non-pre-
specified subgroup of diabetic patients who were
being treated with insulin or oral hypoglycaemic
agents (n = 353), the 5-year survival rates were
higher in the CABG group compared with the PTCA
group (80.6% vs. 65.5%, respectively; p = 0.003),
mainly due to the lower 5-year cardiac mortality
rates (5.8% vs. 20.6%, respectively; p = 0.0003) 
[12, 13]. The additional benefit of CABG was limited
to the patients who received at least 1 internal
mammary artery (IMA) graft; when only saphenous
vein grafts (SVGs) were used, 5-year cardiac mor-
tality was similar in the CABG and PTCA groups [12,
13]. In contrast, 5-year cardiac mortality rates did
not differ in non-diabetic patients allocated to CABG
or PTCA (4.7% and 4.8%, respectively; p = 0.91) [12].
At 10-year follow-up, angina rates were similar in
the 2 revascularization strategies but subsequent
revascularization rates were higher in the PTCA
group than in the CABG group (76.8% vs. 20.3%, 
p < 0.001) [14]. In the subgroup of patients with
treated T2DM, the CABG group had higher survival
rates than the PTCA group (57.8% vs. 45.5%, respec-
tively; p = 0.025) [14]. These results of the BARI tri-
al support the use of CABG over PTCA in patients
with T2DM even though this subgroup was not
specified by the study protocol. In addition, there
was no comparison of revascularization with med-
ical treatment alone. Furthermore, lipid and blood
pressure targets and PCI techniques as well as CABG
perioperative morbidity and mortality have sub-
stantially changed since the publication of the BARI
initial papers (1996-1997). The same applies to oth-
er trials performed during the same time period. 
The Coronary Angioplasty versus Bypass Revas-
cularization Investigation (CABRI) trial, published
15 years ago, also supports the use of CABG in dia-
betic patients [15,  16]. The CABRI trial randomized
1,054 patients (125 (11.9%) with T2DM) with symp-
tomatic multivessel CHD to PTCA or CABG. Diabet-
ic patients who underwent PTCA had higher mor-
tality rates compared with non-diabetic patients
(22.6% vs. 9.4%, respectively; p = 0.001) [15, 16]. In
contrast, when CABG was performed, mortality
rates did not differ significantly in diabetic and non-
diabetic patients (12.5% and 6.8%, respectively; 
p = NS); this difference despite being nearly dou-
ble was not significant, probably due to the small
number of diabetic patients included in the study.Arch Med Sci 6, December / 2011 1069
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Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are
already on optimal medical treatment?
The Emory Angioplasty versus Surgery Trial (EAST),
another “old” trial, did not show a survival (mid- or
long-term) advantage for CABG in patients with
multivessel CHD; however, there were no subgroup
analyses in diabetic patients (23% of the study 
population) [17]. In an observational study with
a similar population (n = 3,220; 24% with T2DM)
published in 1994, diabetic patients receiving either
PTCA or CABG had significantly poorer survival com-
pared with non-diabetics (p < 0.0001). However,
there was no significant differential effect of dia-
betes on outcome between patients treated with
PTCA and those undergoing CABG (p = 0.91) [18].
A larger cohort study in 146,786 patients undergo-
ing CABG (28.4% with T2DM) showed that the 
30-day mortality was higher in diabetic patients
(3.7% vs. 2.7% in non-diabetic patients; adjusted
HR 1.23; 95% CI 1.15-1.32, p = 0.002) [19]. Stroke,
renal failure and infections also occurred more fre-
quently in patients with T2DM. Interestingly, some
studies showed that pretreatment of patients
undergoing CABG or PCI with statins might improve
outcome [20-23]. Therefore, the lower use of statins
might have influenced the results of older trials. 
Some data suggest that CABG might be benefi-
cial even in low-risk patients with ACS [24]. In a ret-
rospective analysis of a nationwide database in Por-
tugal (12,988 patients with ACS), 267 patients
underwent CABG during the index hospitalization
(group A) and 12,721 did not (group B). Group B
patients were further divided into 2 subgroups:
those submitted to PCI during the index hospital-
ization (group B1; n = 3,948) and those who were
not (group B2; n = 8,773). The prevalence of T2DM
was 32%, 23% and 28% in Groups A, B1 and B2,
respectively. In this analysis, early CABG was asso-
ciated with very low in-hospital mortality (1.1%)
although it was performed in higher-risk patients
and even when compared with the mortality of the
lower-risk population not submitted to early CABG
(2.2% in patients undergoing PCI and 6.8% in those
who were not submitted to early mechanical revas-
cularization, p < 0.05 vs. CABG) [24]. This report was
the first to raise the issue of optimal treatment of
ACS and the need for studies comparing the out-
come of CABG, PCI and intensive medical treatment
in patients with ACS with or without T2DM. During
the last decade, PCI is gaining ground over CABG
and medical treatment in patients with ACS [25].
“Rescue”, “elective” and “early” PCI is extensively
used for the treatment of ACS especially after the
generalized  use  of  drug-eluting  stents  (DES), 
GbIIb/IIIa inhibitors and dual antiplatelet (clopido-
grel plus aspirin) treatment [25]. However, PCI is still
underused in diabetic patients with ACS [10]. 
The studies mentioned above included patients
with either ACS or stable CHD and their results have
several limitations. Individual trials and meta-analy-
ses show that in non-diabetic patients with multi-
vessel CHD, CABG and PCI yield comparable long-
term results in terms of hard endpoints (cardiac
death or MI), but subsequent revascularization was
more frequently necessary in patients undergoing
PCI [25]. In contrast, diabetic patients appear to
benefit more from CABG than from angioplasty, as
shown in the BARI and CABRI trials [12-16]. These
findings were also supported by the results of the
Medicine, Angioplasty, or Surgery Study (MASS II)
[26, 27]. MASS II randomly assigned 611 patients
with stable multivessel CHD to medical treatment,
CABG or PCI. In MASS II, 190 patients had T2DM
(medical treatment n = 75; PCI: n = 56; CABG: 
n = 59). The incidence of the primary endpoint (car-
diac death, ST elevation MI (STEMI) and revascu-
larization) did not differ between PCI and contin-
ued medical therapy, whereas CABG was superior
to both [26, 27]. These results seem to contradict
those of the 2 older Randomized Intervention Treat-
ment of Angina-1 and 2 (RITA-1 and 2) studies [28,
29], which compared PCI with CABG (RITA-1 [28])
and PCI with medical treatment alone (RITA-2 [29]).
RITA-1 randomized 1,011 patients with CHD (45%
single-vessel, 55% multivessel, 62 patients (6.1%)
with T2DM) and showed a trend toward lower mor-
tality in the PTCA than in the CABG group with no
difference in total health-service costs over 5 years
between the 2 strategies [28]. In RITA-2 (n = 1,018
CHD patients considered suitable for either PTCA
or continuing medical treatment alone), early inter-
vention with PTCA was associated with greater
symptomatic improvement, especially in patients
with more severe angina [29]. The investigators of
RITA-2 suggested that when managing patients
with angina, clinicians should balance these bene-
fits against the small excess hazard of procedure-
related complications associated with PTCA [29].
However, the cost of an initial strategy of PTCA
exceeded that of an initial strategy of medical man-
agement by 74% over 3 years [30]. On the other
hand, the Steno-2 study clearly demonstrated the
value of multifactorial, target-driven, evidence-
based medical intervention alone, aiming at all
modifiable risk factors in patients with T2DM at
high risk for macrovascular complications [31]. In
Steno-2, medical treatment alone resulted in sig-
nificant reductions (by more than 50%) in 7-year
CVD morbidity and mortality rates [31]. Similarly,
even a short-term (6-month) low-cost best practice
implementation programme was associated with
up to 44% reduction in estimated CVD risk in 578
patients with DM [32].
The recently published Bypass Angioplasty Revas-
cularization Investigation 2 Diabetes (BARI 2D)
trial provides new insight in the management of
diabetic patients with stable CHD [33, 34]. In this
study, 2,368 diabetic patients with stable CHD were1072 Arch Med Sci 6, December / 2011
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randomly assigned, according to a 2 × 2 factorial
design, to receive (1) tight glycaemic control with
insulin sensitization vs. insulin provision aiming at
HbA1c ≤ 7.0%, and (2) intensive medical manage-
ment with either prompt coronary revasculariza-
tion or with coronary revascularization at a later
date and only if clinically indicated. The 5-year car-
diac mortality rates did not differ between revas-
cularization plus intensive medical therapy and
intensive medical therapy alone (5.9% vs. 5.7%,
respectively; p = 0.38) or between insulin sensiti-
zation and insulin provision (5.7% vs. 6%; p = 0.76).
In the 763 patients who underwent CABG (i.e.
patients with more extensive CHD), MI was less fre-
quent in the revascularization plus intensive med-
ical therapy group compared with intensive med-
ical therapy alone (10.0% vs. 17.6%, respectively; 
p = 0.003). The composite endpoints of all-cause
death or MI (21.1% vs. 29.2%, respectively; p = 0.01)
and cardiac death or MI (p = 0.03) were also less
frequent in this group [33, 34]. However, prompt
coronary revascularization was significantly more
expensive than medical therapy alone. The high ini-
tial costs of CABG and PCI were only partially off-
set by later cost savings during the 4 years of fol-
low-up [35]. Cost-effectiveness analyses based on
4-year follow-up data favoured the strategy of med-
ical therapy alone over prompt revascularization
and the strategy of insulin provision over insulin
sensitization. Overall, the BARI 2D results suggest
that in patients with T2DM and stable CHD with-
out angina, intensive medical therapy alone should
be the first-line strategy. In contrast, in patients
with angina that affects quality of life, intensive
medical therapy and prompt CABG appears to be
the preferred strategy [33-35]. 
Outside the context of RCTs, evidence-based
medical  treatment  and  revascularization  also
appear to be beneficial in diabetic patients with
CHD. The recently published Euro Heart Survey on
Diabetes and Heart assessed the impact of med-
ical treatment and revascularization on mortality
and CVD events in 3,488 patients with CHD (41%
with T2DM) [2]. Only 44% of those with T2DM and
43% of those without T2DM received evidence-
based medical treatment, while 34% and 40%,
respectively, underwent revascularization. Medical
treatment and revascularization had comparable
favourable effects on the outcome of all patients
with CHD. In diabetic patients clinical benefit was
more pronounced compared with non-diabetics.
A substantially lower number of diabetic patients
needed to be treated for 1 year to prevent 1 death
(24 in the T2DM group compared with 1,826 in
patients with normal glucose metabolism) or to
avoid a fatal or non-fatal CVD event (32 vs. 141,
respectively) [2]. These results suggest that patients
with both T2DM and CHD benefit substantially
more than patients with CHD alone from combined
medical treatment and revascularization.
In recent years, the outcome of revasculariza-
tion  procedures  has  been  improved  by  the 
introduction of novel medical strategies such as 
GbIIa/IIIb inhibitors, dual antiplatelet therapy (clopi-
dogrel plus aspirin) and aggressive statin pre-treat-
ment [20-23] as well as by the use of DES and
improved surgical methods such as multiple arte-
rial grafting (e.g. bilateral IMA grafts [36]) and off-
pump surgery [11, 25]. Therefore, the results of old-
er studies assessing revascularization and medical
treatment in patients with CHD may no longer be
valid, and more up-to-date trials are needed. For
example, the use of DES reduces repeat revascu-
larization rates [11, 25]. A meta-analysis showed that
DES yield better early and mid-term results com-
pared with bare metal stents (BMS) in diabetic
patients [37]. In this context, it is of interest that
a very recent study comparing PCI (using exclusively
DES) with CABG for multivessel CHD in diabetic
patients suggested that a clinical judgment-based
revascularization by DES-PCI is not associated with
worse 2-year outcome compared with CABG [38].
Another study included 411 consecutive "real-world"
patients (40.3% with ACS and 15% with T2DM)
undergoing PCI with DES by a single operator
(63.5% of the patients in 1 vessel and 36.5% in 
> 1 vessel) between 2003 and 2006 [39]. Only 
9 patients died during the 1 to 5-year follow up.
Therefore, in "real-world" patients at increased risk
of in-stent restenosis with BMS, "off-label" DES
implantation might reduce the risk of late compli-
cations, particularly in-stent restenosis. However,
DES use might lead to acute late stent thrombosis,
a serious but relatively rare complication that may
be accompanied by in-stent restenosis [39]. In this
context, the Drug-Eluting Stents in the Real World
(DESIRE) Registry [40] recently reported long-term
clinical outcomes from 2,084 patients (28.9% with
T2DM and 40.7% with ACS) undergoing PCI with
DES (2,864 lesions and 3,120 DES). Target lesion
revascularization was performed in 3.3% of the
patients during follow-up (2.6 ±1.2 years). The 
STEMI occurred in only 0.7% of the patients and 
in-stent thrombosis in 1.6% (n = 33). These results
also suggest that the use of DES in an unselected
population, including a high percentage of dia  betic
patients, has an acceptable rate of adverse clinical
events [40].
Another recent study assessed 508 patients
undergoing complete (41.7%) or incomplete revas-
cularization (58.3%) with PCI using DES [41]. Dur-
ing a median follow-up of 27 months, the HR for
the primary composite endpoint (cardiac death, 
MI or repeat revascularization) was 0.43 (95% CI
0.29-0.63, p < 0.0001) with complete revasculariza  -
tion compared with incomplete revascularization.Arch Med Sci 6, December / 2011 1073
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Complete revascularization was also associated
with better outcomes in terms of the secondary
endpoints: cardiac death, 0.37 (95% CI 0.15-0.92, 
p =  0.03),  cardiac  death  or  MI,  0.34  (95%  CI 
0.16-0.75, p = 0.008) and any repeat revasculariza-
tion, 0.45 (95% CI 0.29-0.69, p = 0.0003) [41]. Thus,
complete revascularization with DES-PCI in patients
with multivessel CHD may be associated with low-
er rates of long-term adverse events than incom-
plete revascularization [41].
A recent non-randomized study from China com-
pared CABG (n = 282) with DES-PCI (n = 363) in
consecutive diabetic patients with multivessel CHD
[42]. At 12 months after the index revascularization
procedure, total mortality rates were similar in the
CABG and DES group (3.2% vs. 3.0%, respectively;
p = 0.46) [42]. However, the rate of major adverse
CVD events was lower in the CABG group (7.8% vs.
17.9% in the PCI group; HR 0.15, 95% CI 0.06-0.37,
respectively; p < 0.001) mainly due to less repeat
revascularization  (1.4%  vs.  11.6%,  respectively; 
HR 0.02, 95% CI 0.01-0.13, p < 0.001) [42]. The
increased rate of repeat revascularization in the PCI
group was partly due to the high restenosis rate in
diabetic patients [42]. The aforementioned studies
are summarized in Table I.
Comment
It is clear that diabetic patients with CHD bene-
fit more than non-diabetic patients from medical
treatment alone [2, 43], PCI with DES [2, 33, 34, 40]
and CABG [33, 34, 42]. According to a recent report
from the ACC [43], the following variables should be
considered when deciding on the use of revascu-
larization: a) clinical presentation (ACS or stable 
angina), b) severity of angina (asymptomatic, Cana-
dian Cardiovascular Society class I, II, III or IV), 
c) extent of ischaemia on non-invasive testing and
the presence of other prognostic factors, such as
congestive heart failure or impaired left ventricular
function, d) extent of medical therapy, and e) extent
of anatomical disease (1-, 2- or 3-vessel disease, with
or without proximal left anterior descending artery
or left main coronary disease). Revascularization
(CABG or PCI according to indications and individ-
ual presentation) was considered appropriate in
patients presenting with ACS earlier than 12 h after
the onset of symptoms as well as in patients with
intolerable angina despite appropriate medical ther-
apy and evidence of intermediate- to high-risk find-
ings on non-invasive testing [43, 44].  
Another important consideration when com-
paring revascularization strategies and medical
treatment in diabetic patients with CHD is cost-
effectiveness. We previously reported in a subgroup
analysis of the GREACE (GREek Atorvastatin and
CHD Evaluation) study a cost of US $6,200 per qual-
ity-adjusted life-year (QALY) gained with aggressive
medical treatment vs. usual care in diabetic patients
with CHD [45]. In the Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation
(COURAGE) trial [46, 47], which included 766 dia-
betic patients (34% of the study population), PCI
did not decrease mortality or MI more than optimal
medical therapy in patients with stable CHD. A cost-
effectiveness analysis in this trial also favoured
medical treatment ($6,661 for medical treatment
vs. $19,605 for PCI/gained year of life) [47]. In RITA-3
cost-effectiveness analysis [48] showed that, in
patients presenting with non-ST elevation ACS who
were at high risk for further cardiac events, includ-
ing patients with diabetes, an early interventional
strategy was associated, in 95% of cases, with
a gain in QALYs. The additional cost of this inter-
vention was likely to be considered acceptable (at
a threshold of $20,000 per QALY) when compared
with a conservative strategy [48].
Several studies are designed to compare CABG
and DES-PCI in diabetic patients. CABG is the estab-
lished method of revascularization in diabetic
patients with multivessel CHD, but with advances
in PCI, there is some uncertainty whether CABG
remains the preferred method of revascularization.
The CARDia (Coronary Artery Revascularization in
Diabetes) Trial [49] was designed to answer this
question. The one-year results of CARDia suggest
that the primary endpoint (a composite of rate of
death, MI, and stroke) was similar in CABG and PCI
(both BMS and DES) groups (10.5% vs. 13.0%,
respectively, p = 0.39) [49]. All-cause mortality rates
were identical (3.2%); however, the rate of the com-
posite secondary endpoint of death, MI, stroke, or
repeat revascularization favoured CABG (11.3% vs.
19.3%, HR 1.77; 95% CI 1.11-2.82; p = 0.02, respec-
tively), an effect driven by a higher rate of MI in the
PCI group [49]. However, when the patients who
underwent CABG were compared with the subset
of patients who received DES-PCI (69% of patients),
the primary outcome rates were 12.4% and 11.6%
(HR: 0.93, 95% CI: 0.51-1.71; p = 0.82), respectively.
Thus, the one-year results of CARDia, the first ran-
domized trial of coronary revascularization in dia-
betic patients, showed that DES-PCI is non-inferi-
or to CABG [49].
Ongoing trials
Several other studies comparing CABG and DES-
PCI in diabetic patients are underway, including
FREEDOM (Comparison of Two Treatments for Mul-
tivessel Coronary Artery Disease in Individuals with
Diabetes) [http://www.clinicaltrials.gov.], VA-CARDS
(Coronary Artery Revascularization in Diabetes)
[http://www.clinicaltrials.gov.] and SYNTAX (TAXUS
Drug-Eluting Stent Versus Coronary Artery Bypass
Surgery for the Treatment of Narrowed Arteries)
[http://www.clinicaltrials.gov.]. The results of these1074 Arch Med Sci 6, December / 2011
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trials are expected to provide valuable information
on the appropriate management of very high-risk
patients with both CHD and T2DM. 
Conclusions
Overall, in patients with DM we should focus on
intensive multifactorial intervention aiming at tight
blood pressure, glucose and lipid control that can
reduce both microvascular and macrovascular com-
plications and improve survival [50-52]. The deci-
sion regarding the optimal choice of revasculariza-
tion procedure in patients with DM remains to be
established. Ongoing trials using the latest PCI tech-
nology combined with aggressive best medical
treatment will hopefully provide clinical guidance.
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